Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects

NCT02626923 is registered in ClinicalTrials.gov with Nicholaos C Bellos, MD as lead sponsor.

NCT NCT02626923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects
Lead sponsor
Nicholaos C Bellos, MD
Phase
Observational
Overall status
Completed
Start date
July 31, 2012
Completion date
March 31, 2014
Enrollment
51 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

drug-induced hypotension